Oculus Innovative Sciences, Inc., a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, has received a new 510(k) clearance from the US Food and Drug Administration (FDA) for the company's new post-dermal-procedures product.

Under the supervision of a healthcare professional, the product is intended for the removal of foreign material including microogranisms and debris from postdermal procedures.

"Within my practice I utilize the Microcyn Technology (hypochlorous acid or HOCl) post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections. I find these HOCl products to be safer, non-cytotoxic and a more effective alternative to povidone-iodine and chlorhexidine. Now, with this approval from the FDA, I believe my peers will benefit from adding Microcyn-based products to their treatment protocols," said Dr. Michael Gold, board-certified dermatologist and cosmetic surgeon, and founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, the Laser & Rejuvenation Center and Tennessee Clinical Research Center, all located in Nashville, Tennessee.

Oculus' dermatology division, IntraDerm, will begin marketing the postdermal-procedures product in the United States beginning in March 2017.